Skip to main content

Table 1

From: 0315. The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers

 

mean(95% CI)

mean(95% CI)

GMR (95% CI)

Ribavirin PK parameters

phase I (ribavirin alone)

phase 3 (ribavirin with raltegravir)

 

T ½, h

6.04 (5.29 - 6.90)

6.77 (5.56 - 8.25)

1.12 (0.86 - 1.46)

Tmax, h

1.61 (1.12 - 2.11)

2.23 (1.65 - 3.01)

1.39 (1.08 - 1.78)

Cmax, ng/mL

630.09 ( 490.91 - 808.54)

496.71 (407.38 - 605.76)

0.79 (0.62 - 1.00)

Cmin, ng/mL

184.71 (148.59 - 229.61)

186.98 (157.83 - 221.56)

1.01 (0.87 - 1.18)

AUC0-12

3325.83 (2703.34 - 4091.66)

2941.03 (2323.27 - 3722.20)

0.88 (0.73 - 1.07)